A Phase Ia Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous EB070 Injection in Healthy Volunteers
Latest Information Update: 02 Mar 2026
At a glance
- Drugs EB 070 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
Most Recent Events
- 02 Mar 2026 New trial record